Equities Analysts Offer Predictions for ACTU Q3 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Investment analysts at HC Wainwright cut their Q3 2025 earnings estimates for shares of Actuate Therapeutics in a research report issued on Monday, August 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.25) for the quarter, down from their previous forecast of ($0.18). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.05) EPS and FY2026 earnings at ($1.02) EPS.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Actuate Therapeutics Stock Performance

NASDAQ:ACTU opened at $7.68 on Wednesday. The firm’s 50-day moving average is $7.08 and its 200-day moving average is $7.96. Actuate Therapeutics has a 52-week low of $5.47 and a 52-week high of $11.99.

Insider Activity at Actuate Therapeutics

In other news, Director Aaron G.L. Fletcher purchased 71,428 shares of Actuate Therapeutics stock in a transaction on Friday, June 27th. The shares were purchased at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the transaction, the director directly owned 196,428 shares in the company, valued at approximately $1,374,996. This represents a 57.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Equity Cof Lp Bios purchased 71,428 shares of Actuate Therapeutics stock in a transaction on Friday, June 27th. The stock was purchased at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the transaction, the director owned 196,428 shares of the company’s stock, valued at approximately $1,374,996. This represents a 57.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 214,284 shares of company stock valued at $1,499,988 over the last quarter. 69.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Actuate Therapeutics

A number of large investors have recently modified their holdings of the stock. BIOS Capital Management LP lifted its position in shares of Actuate Therapeutics by 0.7% during the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock worth $60,887,000 after purchasing an additional 71,428 shares in the last quarter. Voss Capital LP lifted its holdings in Actuate Therapeutics by 101.0% in the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock valued at $1,748,000 after buying an additional 143,759 shares during the period. Geode Capital Management LLC lifted its holdings in Actuate Therapeutics by 252.5% in the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after buying an additional 84,561 shares during the period. Sigma Planning Corp lifted its holdings in Actuate Therapeutics by 47.3% in the first quarter. Sigma Planning Corp now owns 23,675 shares of the company’s stock valued at $160,000 after buying an additional 7,600 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after buying an additional 11,105 shares during the period.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.